A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer

Respiratory Medicine

Volumn 97, Issue 7, 2003, Pages 796-803

  Ho, James C M ^a   Tan, E H ^b   Leong, S S ^b   Wang, C H ^c   Sun, Y ^d   Li, R ^e   Wahid, M I A ^f   Jusuf, A ^g   Liao, M ^h   Guan, Z ⁱ   Handoyo, P ^j   Huang, J S ^c   Chan, V ^k   Luna, G ^l   Tsang, K W T ^a   Lam, W K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CANCER HOSPITAL   (China)

^e XI'AN MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF MALAYA   (Malaysia)

^g Indonesia Persahabatan Hospital   (Indonesia)

^h SHANGHAI CHEST HOSPITAL   (China)

ⁱ SUN YAT SEN UNIVERSITY   (China)

^j Sumber Waras Hospital   (Indonesia)

^k UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^l ST LUKE S MEDICAL CENTER   (Philippines)

more..

Author keywords

Cisplatin; Docetaxel; First line; Non small cell lung cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; MAGNESIUM SULFATE; ONDANSETRON; POTASSIUM CHLORIDE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; ASIAN; ASTHENIA; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDEMA; FEMALE; HISTOLOGY; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DYSFUNCTION; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; OTOTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SEPSIS; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0038482181     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)00033-7     Document Type: Article

References (32)

1. Lam WK, Tsang KW, Ip MS. Chemotherapy for advanced (stage III B and stage IV) non-small cell lung cancer: the Hong Kong perspective. Respirology 1998;3:145-9.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: meta-analysis using updated data in individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
3. Johnson DH. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer. A historical perspective and the Eastern Cooperative Oncology Group experience. Chest 2000;117:133S-7S.
4. Bunn PA, Kelly K. New combinations in the treatment of lung cancer. A time for optimism. Chest 2000;117:138S-43S.
5. Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 1996;6(1):443-57.
6. Bissery MC. Preclinical pharmacology of docetaxel. Eur J Cancer 1995;31A(Suppl 4):S1.
7. Miller VA, Kris MG. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Semin Oncol 2000;27(2 Suppl 3):3-10.
8. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355:1176-8.
9. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multi-center, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27(3):145-57.
10. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095-103.
11. Fossella FV, Rigas J. The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. Semin Oncol 1999;26(3 Suppl 11):9-12.
12. Alexopoulos K, Kouroussis C, Androulakis N, et al. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Cancer Chemother Pharmacol 1999;43(3):257-62.
13. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995;13(3):645-51.
14. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small cell lung cancer: results of a phase II multicentre trial. J Clin Oncol 2000;18(1):131-5.
15. Gridelli C, Frontini L, Barletta E, et al. Single agent docetaxel plus granulocyte-colony stimulating factor G-CSF in previously treated patients with advanced non-small cell lung cancer A phase II study and review of the literature. Anticancer Res 2000;20(2B):1077-84.
16. Aoe K, Kiura K, Ueoka H, et al. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res 1999;19(1A):291-9.
17. Belani CP. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments. Semin Oncol 1999;26 (3 Suppl 10):15-8.
18. Le Chevalier T, Monnier A, Douillard JY, et al. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 1998;34(13):2032-6.
19. Georgoulias V, Androulakis N, Dimopoulos AM, et al. First-line treatment of advanced non-small cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 1998;9(3):331-4.
20. Zalcbery J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer. J Clin Oncol 1998;16(5):1948-53.
21. Belani C, Lynch T. Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management. Semin Oncol 2001;28(1 Suppl 2):10-4.
22. Millward MF, Zalcberg J, Bishop JF, et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 1997;15(2):750-8.
23. McLaughlin JR, Boyd NF. Epidemiology of cancer. In: Tannock IF, Hill RP, editors. The Basic science of oncology. 3rd Ed.. New York: McGraw-Hill, Health Professions Division, 1998. p. 6-25.
24. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
25. Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
26. Lam B, Lam WK, Lam CL, et al. Adenocarcinoma of the lung in Chinese patients: a re-visit and some perspectives from the literature. Postgrad Med J 2001;77:708-12.
27. Lee CT, Kang KH, Koh Y, et al. Characteristics of lung cancer in Korea, 1997. Lung Cancer 2000;30:15-22.
28. Seow A, Duffy SW, Ng TP, McGee MA, Lee HP. Lung cancer among Chinese females in Singapore 1968-1992: time trends, dialect group differences and implications for aetiology. Int J Epidemiol 1998;27:167-72.
29. Perng DW, Perng RP, Kuo BIT, Chiang SC. The variation of cell type distribution in lung cancer: a study of 10910 cases at a medical center in Taiwan between 1970 and 1993. Jpn J Clin Oncol 1996;26:229-33.
30. Du YX, Cha Q, Chen XW, et al. An epidemiological study of risk factors for lung cancer in Guangzhou, China. Lung Cancer 1996;14(Suppl 1):S9-37.
31. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
32. Rodriguez J, Pawel J, Pluzanska A, et al. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:1252 (Abstract).